search icon
immp-img

Immutep ltd adr share price

IMMP
NMQ
$4.06
-$0.28
(-6.45%)
1D
Industry: Biotechnology Sector: Health Care

Immutep ltd adr analyst forecast

Immutep ltd adr share price chart

Immutep ltd adr key stock metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$31.98M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
9.61K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.17 L
$66.39 H
$4.06

About immutep ltd adr, common stock

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. more

Industry: BiotechnologySector: Health Care

Immutep ltd adr stock returns

Time FrameIMMPSectorS&P500
1-Week Return-12.69%-0.79%2.19%
1-Month Return-44.35%-0.02%1.72%
3-Month Return-54.66%1.61%4.24%
6-Month Return-42.9%14%18.18%
1-Year Return-90.24%15.85%16.42%
3-Year Return-88.53%28.08%80.32%
5-Year Return-94.69%30.97%77.61%
10-Year Return-93.01%132.49%262.71%

Immutep ltd adr financials

Jun '22Jun '23Jun '24Jun '25Jun '265YR TREND
Total Revenue170.37K3.51M3.84M5.04M14.24M[{"date":"2022-06-30","value":1.2,"profit":true},{"date":"2023-06-30","value":24.62,"profit":true},{"date":"2024-06-30","value":26.98,"profit":true},{"date":"2025-06-30","value":35.42,"profit":true},{"date":"2026-06-30","value":100,"profit":true}]
Cost of Revenue2.06M2.06M41.55M61.41M2.42M[{"date":"2022-06-30","value":3.36,"profit":true},{"date":"2023-06-30","value":3.36,"profit":true},{"date":"2024-06-30","value":67.65,"profit":true},{"date":"2025-06-30","value":100,"profit":true},{"date":"2026-06-30","value":3.94,"profit":true}]
Gross Profit(1.89M)1.44M(37.70M)(56.37M)11.82M[{"date":"2022-06-30","value":-16.02,"profit":false},{"date":"2023-06-30","value":12.22,"profit":true},{"date":"2024-06-30","value":-319,"profit":false},{"date":"2025-06-30","value":-476.89,"profit":false},{"date":"2026-06-30","value":100,"profit":true}]
Gross Margin(1111.18%)41.19%(981.42%)(1117.55%)83.01%[{"date":"2022-06-30","value":-1338.6,"profit":false},{"date":"2023-06-30","value":49.62,"profit":true},{"date":"2024-06-30","value":-1182.28,"profit":false},{"date":"2025-06-30","value":-1346.28,"profit":false},{"date":"2026-06-30","value":100,"profit":true}]
Operating Expenses32.55M44.94M50.40M70.06M93.87M[{"date":"2022-06-30","value":34.67,"profit":true},{"date":"2023-06-30","value":47.87,"profit":true},{"date":"2024-06-30","value":53.69,"profit":true},{"date":"2025-06-30","value":74.63,"profit":true},{"date":"2026-06-30","value":100,"profit":true}]
Operating Income(33.94M)(77.69M)(88.10M)(126.42M)(82.05M)[{"date":"2022-06-30","value":-3393755400,"profit":false},{"date":"2023-06-30","value":-7768849200,"profit":false},{"date":"2024-06-30","value":-8810418600,"profit":false},{"date":"2025-06-30","value":-12642179500,"profit":false},{"date":"2026-06-30","value":-8204581700,"profit":false}]
Total Non-Operating Income/Expense1.76M38.71M49.24M70.24M7.35M[{"date":"2022-06-30","value":2.5,"profit":true},{"date":"2023-06-30","value":55.11,"profit":true},{"date":"2024-06-30","value":70.1,"profit":true},{"date":"2025-06-30","value":100,"profit":true},{"date":"2026-06-30","value":10.46,"profit":true}]
Pre-Tax Income(32.21M)(39.90M)(42.72M)(61.43M)(77.57M)[{"date":"2022-06-30","value":-3221079200,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false},{"date":"2025-06-30","value":-6143416500,"profit":false},{"date":"2026-06-30","value":-7757165600,"profit":false}]
Income Taxes34.00----[{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true},{"date":"2026-06-30","value":"-","profit":true}]
Income After Taxes(32.21M)(39.90M)(42.72M)(61.43M)(77.57M)[{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false},{"date":"2025-06-30","value":-6143416500,"profit":false},{"date":"2026-06-30","value":-7757165600,"profit":false}]
Income From Continuous Operations(32.21M)(39.90M)(42.72M)(61.43M)(77.57M)[{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false},{"date":"2025-06-30","value":-6143416500,"profit":false},{"date":"2026-06-30","value":-7757165600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true},{"date":"2026-06-30","value":"-","profit":true}]
Net Income(32.21M)(39.90M)(42.72M)(61.43M)(77.57M)[{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false},{"date":"2025-06-30","value":-6143416500,"profit":false},{"date":"2026-06-30","value":-7757165600,"profit":false}]
EPS (Diluted)(0.37)(0.44)(0.36)(0.42)(0.53)[{"date":"2022-06-30","value":-37,"profit":false},{"date":"2023-06-30","value":-44,"profit":false},{"date":"2024-06-30","value":-36,"profit":false},{"date":"2025-06-30","value":-42,"profit":false},{"date":"2026-06-30","value":-53,"profit":false}]

Immutep ltd adr ratios

Immutep ltd adr liquidity ratios

These ratios help you determine the liquidity of the company. Higher is better.

IMMP
Cash Ratio 4.86
Current Ratio 5.69
Quick Ratio 5.69

Immutep ltd adr asset efficiency ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMMP
ROA (LTM) -95.24%
ROE (LTM) -98.86%

Immutep ltd adr liability ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMMP
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Immutep ltd adr valuation ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMMP
Trailing PE NM
Forward PE 0.01
P/S (TTM) 3.64
P/B 0.86
Price/FCF NM
EV/R -1.01
EV/Ebitda 0.17

Faqs

What is Immutep Ltd ADR share price today?

Immutep Ltd ADR (IMMP) share price today is $4.06

Can Indians buy Immutep Ltd ADR shares?

Yes, Indians can buy shares of Immutep Ltd ADR (IMMP) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMMP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immutep Ltd ADR be purchased?

Yes, you can purchase fractional shares of Immutep Ltd ADR (IMMP) via the Vested app. You can start investing in Immutep Ltd ADR (IMMP) with a minimum investment of $1.

How to invest in Immutep Ltd ADR shares from India?

You can invest in shares of Immutep Ltd ADR (IMMP) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMMP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immutep Ltd ADR shares

What is Immutep Ltd ADR 52-week high and low stock price?

The 52-week high price of Immutep Ltd ADR (IMMP) is $66.39. The 52-week low price of Immutep Ltd ADR (IMMP) is $4.17.

What is Immutep Ltd ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Immutep Ltd ADR (IMMP) is

What is Immutep Ltd ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immutep Ltd ADR (IMMP) is 0.86

What is Immutep Ltd ADR dividend yield?

The dividend yield of Immutep Ltd ADR (IMMP) is 0.00%

What is the Market Cap of Immutep Ltd ADR?

The market capitalization of Immutep Ltd ADR (IMMP) is $31.98M

What is Immutep Ltd ADR's stock symbol?

The stock symbol (or ticker) of Immutep Ltd ADR is IMMP

How Can Investors Use Immutep Ltd ADR Share Price Data for Long-Term Investment Decisions?

Consider the share price of Immutep Ltd ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Immutep Ltd ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Immutep Ltd ADR shares for Indian investors?

When investing in Immutep Ltd ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Immutep Ltd ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Immutep Ltd ADR share price with other stocks in the same sector?

Rather than merely checking the share price of Immutep Ltd ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Immutep Ltd ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top